252 related articles for article (PubMed ID: 36944847)
1. Treatment of hydroxyurea-resistant/intolerant polycythemia vera: a discussion of best practices.
Kuykendall AT
Ann Hematol; 2023 May; 102(5):985-993. PubMed ID: 36944847
[TBL] [Abstract][Full Text] [Related]
2. Where to Turn for Second-Line Cytoreduction After Hydroxyurea in Polycythemia Vera?
Nazha A; Gerds AT
Oncologist; 2016 Apr; 21(4):475-80. PubMed ID: 26975864
[TBL] [Abstract][Full Text] [Related]
3. Management of hydroxyurea resistant or intolerant polycythemia vera.
Raman I; Pasricha SR; Prince HM; Yannakou CK
Leuk Lymphoma; 2021 Oct; 62(10):2310-2319. PubMed ID: 33949918
[TBL] [Abstract][Full Text] [Related]
4. How We Identify and Manage Patients with Inadequately Controlled Polycythemia Vera.
Reiter A; Harrison C
Curr Hematol Malig Rep; 2016 Oct; 11(5):356-67. PubMed ID: 26894383
[TBL] [Abstract][Full Text] [Related]
5. Real-world analysis of main clinical outcomes in patients with polycythemia vera treated with ruxolitinib or best available therapy after developing resistance/intolerance to hydroxyurea.
Alvarez-Larrán A; Garrote M; Ferrer-Marín F; Pérez-Encinas M; Mata-Vazquez MI; Bellosillo B; Arellano-Rodrigo E; Gómez M; García R; García-Gutiérrez V; Gasior M; Cuevas B; Angona A; Gómez-Casares MT; Martínez CM; Magro E; Ayala R; Del Orbe-Barreto R; Pérez-López R; Fox ML; Raya JM; Guerrero L; García-Hernández C; Caballero G; Murillo I; Xicoy B; Ramírez MJ; Carreño-Tarragona G; Hernández-Boluda JC; Pereira A;
Cancer; 2022 Jul; 128(13):2441-2448. PubMed ID: 35417564
[TBL] [Abstract][Full Text] [Related]
6. [Recent advances in polycythemia vera treatment].
Edahiro Y
Rinsho Ketsueki; 2020; 61(9):1187-1194. PubMed ID: 33162515
[TBL] [Abstract][Full Text] [Related]
7. Polycythemia vera: aspects of its current diagnosis and initial treatment.
Silver RT; Abu-Zeinah G
Expert Rev Hematol; 2023 Apr; 16(4):253-266. PubMed ID: 37013802
[TBL] [Abstract][Full Text] [Related]
8. A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 Inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea.
Verstovsek S; Passamonti F; Rambaldi A; Barosi G; Rosen PJ; Rumi E; Gattoni E; Pieri L; Guglielmelli P; Elena C; He S; Contel N; Mookerjee B; Sandor V; Cazzola M; Kantarjian HM; Barbui T; Vannucchi AM
Cancer; 2014 Feb; 120(4):513-20. PubMed ID: 24258498
[TBL] [Abstract][Full Text] [Related]
9. Polycythemia vera and essential thrombocythemia: 2017 update on diagnosis, risk-stratification, and management.
Tefferi A; Barbui T
Am J Hematol; 2017 Jan; 92(1):94-108. PubMed ID: 27991718
[TBL] [Abstract][Full Text] [Related]
10. Polycythemia vera: from new, modified diagnostic criteria to new therapeutic approaches.
Maffioli M; Mora B; Passamonti F
Clin Adv Hematol Oncol; 2017 Sep; 15(9):700-707. PubMed ID: 28949941
[TBL] [Abstract][Full Text] [Related]
11. Polycythemia Vera Management and Challenges in the Community Health Setting.
Gerds AT; Dao KH
Oncology; 2017; 92(4):179-189. PubMed ID: 28095380
[TBL] [Abstract][Full Text] [Related]
12. Real-World Dosing Patterns of Ruxolitinib in Patients With Polycythemia Vera Who Are Resistant to or Intolerant of Hydroxyurea.
Altomare I; Parasuraman S; Paranagama D; Kish J; Lord K; Yu J; Colucci P
Clin Lymphoma Myeloma Leuk; 2021 Nov; 21(11):e915-e921. PubMed ID: 34353779
[TBL] [Abstract][Full Text] [Related]
13. Long-term efficacy and safety of ruxolitinib versus best available therapy in polycythaemia vera (RESPONSE): 5-year follow up of a phase 3 study.
Kiladjian JJ; Zachee P; Hino M; Pane F; Masszi T; Harrison CN; Mesa R; Miller CB; Passamonti F; Durrant S; Griesshammer M; Kirito K; Besses C; Moiraghi B; Rumi E; Rosti V; Blau IW; Francillard N; Dong T; Wroclawska M; Vannucchi AM; Verstovsek S
Lancet Haematol; 2020 Mar; 7(3):e226-e237. PubMed ID: 31982039
[TBL] [Abstract][Full Text] [Related]
14. Ruxolitinib is effective and safe in Japanese patients with hydroxyurea-resistant or hydroxyurea-intolerant polycythemia vera with splenomegaly.
Kirito K; Suzuki K; Miyamura K; Takeuchi M; Handa H; Okamoto S; Gadbaw B; Yamauchi K; Amagasaki T; Ito K; Hino M
Int J Hematol; 2018 Feb; 107(2):173-184. PubMed ID: 28956263
[TBL] [Abstract][Full Text] [Related]
15. Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management.
Tefferi A; Barbui T
Am J Hematol; 2015 Feb; 90(2):162-73. PubMed ID: 25611051
[TBL] [Abstract][Full Text] [Related]
16. Recent advances in the treatment of polycythemia vera.
Duek A; Berla M; Ellis MH
Leuk Lymphoma; 2022 Aug; 63(8):1801-1809. PubMed ID: 35387553
[TBL] [Abstract][Full Text] [Related]
17. Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinib.
Bryan JC; Verstovsek S
Cancer Chemother Pharmacol; 2016 Jun; 77(6):1125-42. PubMed ID: 27017614
[TBL] [Abstract][Full Text] [Related]
18. Evolving Therapeutic Options for Polycythemia Vera: Perspectives of the Canadian Myeloproliferative Neoplasms Group.
Sirhan S; Busque L; Foltz L; Grewal K; Hamm C; Laferriere N; Laneuville P; Leber B; Liew E; Olney HJ; Prchal J; Porwit A; Gupta V
Clin Lymphoma Myeloma Leuk; 2015 Dec; 15(12):715-27. PubMed ID: 26433906
[TBL] [Abstract][Full Text] [Related]
19. Treatment of polycythemia vera.
Dulíček P
Vnitr Lek; 2018; 64(10):955-960. PubMed ID: 30590943
[TBL] [Abstract][Full Text] [Related]
20. Ruxolitinib: a targeted treatment option for patients with polycythemia vera.
Vaddi K; Verstovsek S; Kiladjian JJ
Blood Lymphat Cancer; 2016; 6():7-19. PubMed ID: 31360077
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
